Bartlett, N., Li, H., Knopp, M., Wright, C., Schoder, H., Schwartz, L., Castellino, S., Rutherford, S., Evens, A., Davison, K., Punnett, A., Shipp, M., Kahl, B., Leonard, J., Smith, S., Song, J., Kostakoglu, L., Kelly, K., LeBlanc, M., Friedberg, J., Herrera, A. (2025). Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study. Blood. https://doi.org/10.1182/blood-2025-1851